Brittle asthma

Thorax

Volumn 53, Issue 4, 1998, Pages 315-321

  Ayres, Jon G ^a   Miles, Jon F ^a   Barnes, Peter J ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; HOSPITAL ADMISSION; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; REVIEW;

EID: 0031924483     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.4.315     Document Type: Review

References (74)

1. Turner Warwick M. On observing patterns of airflow obstruction in chronic asthma. Br J Dis Chest 1977;71:73-86.
2. Clark TJH, Hetzel MR. Diurnal variation of asthma. Br J Dis Chest 1977;71:87-92.
3. Connolly CK. Diurnal rhythms in airway obstruction. Br J Dis Chest 1979;73:357-66.
4. Bateman JRM, Clarke SW. Sudden death in asthma. Thorax 1979;34:40-43.
5. Westerman DE, Benatar SR, Portgieter PD, et al. Identification of high risk asthmatic patients. Am J Med 1979;66: 565-572.
6. Hetzel MR, Clark TJH, Branthwaite MA. Asthma: analysis of deaths and ventilatory arrests in hospital. BMJ 1978;408:808-11.
7. British Thoracic Society, British Paediatric Association, Royal College of Physicians of London et al, Guidelines on the management of asthma. Thorax 1993;48(Suppl):SI 24.
8. Boulet L-P, Deschesnes F, Turcotte H, et al. Near fatal asthma: clinical and physiologic features, perception of bronchoconstriction and psychologic profile. J Allergy Clin Immunol 1991;88:838-46.
9. O'Driscoll BRC, Ruffles SP, Ayres JG, et al. Long term treatment of severe asthma with subcutaneous terhutaline. Br J Dis Chest 1988;82:360-5.
10. Miller MR, Dickinson SA, Hitchings DJ. The accuracy of portable peak flow meters. Thorax 1992;47:904-9.
11. Gardner RM, Crapo RO, Jackson BR, et al. Evaluation of accuracy and reproducibility of peak flow meters at 1400 m. Chest 1992;101:948-52.
12. Newman Taylor AJ, Davies RJ, Hendrick DJ, et al. Recurrent nocturnal asthmatic reactions to bronchial provocation tests. Clin Allergy 1979;9:213-9.
13. Beynon HLC, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: the effect of intramuscular progesterone. Lancet 1988;ii:370-2.
14. Miles JF, Cayton RM, Tunnicliffe WS, et al. Increased atopic sensitization in brittle asthma. Clin Exp Allergy 1995;25:1074-82.
15. Carswell F. Thirty deaths from asthma. Arch Dis Child 1985;60:25-8.
16. Wasserfallen JB, Schaller MD, Feihl F, et al. Sudden asphyxic asthma: a distinct entity? Am Rev Respir Dis 1990; 142:108-11.
17. Sur S, Crotty TB, Kephart GM, et al. Sudden onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa. Am Rev Respir Dis 1993;148:713-9.
18. Picado C. Barcelona's asthma epidemics: clinical aspects and intriguing findings. Thorax 1992;47:197-200.
19. Miles JF, Noble K, Matthews HR, et al. Gastro-oesophageal reflux in patients with brittle asthma. Respir Med (submitted for publication).
20. Miles JF, Sapiano S, Cayton RM, et al. Lung function tests in patients with brittle asthma. Am J Respir Crit Care Med 1995;151:A676.
21. Morton NE. Major loci for atopy? Clin Exp Allergy 1992;22: 1041-3.
22. Lemanske Jr RF, Dick EC, Swenson CA, et al. Rhinovirus upper respiratory infection increases airway hyperractivity and late asthmatic reactions. J Clin Invest 1989;83:1-10.
23. Coqueret O, Dugas B, Mencia-Huerta JM, et al. Regulation of IgE production from human mononuclear cells by β-adrenoceptor agonists. Clin Exp Allergy 1995;25:304-11.
24. O'Holloren MJ, Yunginger JW, Offord KP, et al. Exposure to aeroallergens as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med 1991;324:359-63.
25. Ayres JG, Thompson RA. IgG sub-class deficiency in brittle asthma and in patients with recurrent infective exacerbations of asthma. Respir Med 1997;91:464-9.
26. Shaheen MZ, Barker R, Drayson M, et al. Randomised double-blind cross over trial of immunoglobulin replacement therapy in patients with severe asthma. Thorax 1992; 47:254.
27. Loza C, Brostoff J. Peanut allergy. Clin Exp Allergy 1995;25: 493-502.
28. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding severity? Am Rev Respir Dis 1993;148:75-9.
29. Garden GMF, Ayres JG. The psychiatric and social aspects of brittle asthma. Thorax 1993;48:501-5.
30. Miles JF, Garden GM, Tunnicliffe W, et al. Psychological morbidity and coping skills in patients with brittle and non-brittle asthma: a case-control study. Clin Exp Allergy 1997;27:1151-9.
31. Hylatid ME, Finnis S, Irvine SH. A scale for measuring quality of life in adult asthma sufferers. J Psychosom Res 1991;35:99-110.
32. Miles JF, Garden G, Ayres JG. Group therapy in the management of chronic severe asthma. Thorax 1993;48: 1065.
33. Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnoea in patients with a history of near-fatal asthma. N Engl J Med 1994;330:1319-24.
34. Barnes PJ. Poorly perceived asthma. Thorax 1992;47:408-9.
35. Barnes PJ. Blunted perception and death from asthma. N Engl J Med 1994;330:1383-4.
36. Town GI, Allan C. Ventilatory responses to hypoxia and hypercapnia in asthmatics with previous respiratory failure. Aust NZJ Med 1989;19:426-30.
37. Johnson AJ, Somner AR, Stableforth DE, et al. Circumstances of death from asthma. BMJ 1984;288:1870-2.
38. Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969;ii:279-85.
39. Sears MR, Beaglehole R. Asthma morbidity and mortality in New Zealand. J Allergy Clin Immunol 1987;80:383-8.
40. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. BMJ 1968;1:335-9.
41. Crane J, Flatt A, Jackson R, et al. Prescribed fenoterol and death from asthma in New Zealand. Lancet 1989;i:917-22.
42. Pearce N, Beasley R, Crane J, et al. Effect of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-1.
43. Sears MR, Taylor DR, Print DG, et al. Regular inhaled beta agonist treatment in bronchial asthma. Lancet 1990;336: 1991-6.
44. Peters MJ, Adcock IM, Brown CR, et al. Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. Eur J Pharmacol 1995;289:275-81.
45. Garrett JE, Kolbe J, Rea HH, et al. Risk of severe life threatening asthma (SLTA) and type of prescribed β-agonist: an example of confounding by severity. Aust NZ Med J 1994; 24:433.
46. Garrett J, Kolbe J, Richards G, et al. Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand: what lessons have been learned? Thorax 1995;50:303-11.
47. Djukanovic R, Roche UR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-57.
48. Matusiewicz SP, Brown PH, Wallace WAH, et al. Bronchial mucosal inflammation in patients with corticosteroid sensitive (CS) and corticosteroid resistant (CR) chronic asthma. Thorax 1993;48:1060-1.
49. Leung DYM, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid resistant asthma. J Exp Med 1995;181:33-40.
50. Barnes PJ, Kharitonov SA. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
51. Taylor GW, Taylor IK, Black P, et al. Urinary leukotriene E4 following allergen challenge and in patients with acute asthma and allergic rhinitis. Lancet 1989;i:584-8.
52. Corrigan CJ, Haczku A, Gemou-Engesaeth V, et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentration of interleukin-5. Am Rev Respir Dis 1993;147:540-7.
53. 20 and exacerbations. Respir Med 1994;88:613-21.
54. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-9.
55. Virchow JC, Hulscher U, Virchow C. Sputum ECP levels correlate with parameters of airflow obstruction. Am Rev Respir Dis 1992;146:604-6.
56. Keatings VM, Collins PD, Scott DM, et al. Levels of interleukin-8 but not tumour necrosis factor-beta induced sputum discriminates between asthma and chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1996;153:530-4.
57. Barnes PJ. Sensory nerves, neuropeptides and asthma. Ann N Y Acad Sci 1991;629:359-70.
58. Lilly CM, Bai TR, Shore SA, et al. Neuropeptide contents of lungs from asthmatic and non asthmatic subjects. Am J Respir Crit Care Med 1995;151:548-53.
59. Adcock IM, Peters M, Gelder C, et al. Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids. J Mol Endocrinol 1993;11:I-7.
60. Kuwano K, Boskev CH, Par PD, et al. Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:1220-5.
61. Barnes PJ, Adcock IM. Steroid resistant asthma. Q J Med 1995;88:455-68.
62. Adcock IM, Lane SJ, Brown CA, et al. Abnormal glucocorticoid receptor/AP1 interaction in steroid resistant asthma. J Exp Med 1995;182:1951-8.
63. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J 1995;8:899-904.
64. Ayres JG. Subcutaneous terbutaline in the management of brittle asthma. Br J Hosp Med 1992;47:569-71.
65. Ayres JG, Fish DR, Wheeler DC, et al. Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping. BMJ 1984;288:1715-6.
66. Sykes AP, Higgins AH, Ayres JG. Continuous subcutaneous terbutaline is effective in the treatment of brittle asthma by achieving high serum terbutaline levels. Thorax 1987;42: 231.
67. Jarvie DR, Thompson AM, Dyson EH. Laboratory and clinical features of self-poisoning with salbutamol and terbutaline. Clin Chem Acta 1987;305:485-8.
68. Sykes AP, Ayres JG. Further bronchodilatation from low dose inhaled beta 2-agonists in patients receiving infused terbutaline. Thorax 1991;46:319.
69. Wong LB, Miller IF, Yeates DB. Regulation of ciliary beat frequency by autonomic mechanisms in vitro. J Appl Physiol 1988;65:1895-901.
70. Lewis LD, O'Driscoll BRC, Hartley RB, et al. An unusual local reaction to continuous subcutaneous infused terbutaline in unstable asthmatics. Br J Dis Chest 1987;81:189-93.
71. Tunnicliffe WS, Duncanson RC, Fletcher TJ, et al. Site problems in type 1 brittle asthmatics using continuous subcutaneous infusions of terbutaline (CSIT) Thorax 1995;50: (Suppl 2):A74.
72. Sykes AP, Lawson N, Finnegan JA, et al. Creatinine kinase activity in patients with brittle asthma treated with longterm subcutaneous terbutaline. Thorax 1991;46:580-3.
73. Ulrik CS, Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Eur Respir J 1994;7:1003-5.
74. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase, Zileuton, in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.